Cardiac metabolism as a driver and therapeutic target of myocardial infarction
Open Access
- 8 May 2020
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (11), 5937-5954
- https://doi.org/10.1111/jcmm.15180
Abstract
Reducing infarct size during a cardiac ischaemic‐reperfusion episode is still of paramount importance, because the extension of myocardial necrosis is an important risk factor for developing heart failure. Cardiac ischaemia‐reperfusion injury (IRI) is in principle a metabolic pathology as it is caused by abruptly halted metabolism during the ischaemic episode and exacerbated by sudden restart of specific metabolic pathways at reperfusion. It should therefore not come as a surprise that therapy directed at metabolic pathways can modulate IRI. Here, we summarize the current knowledge of important metabolic pathways as therapeutic targets to combat cardiac IRI. Activating metabolic pathways such as glycolysis (eg AMPK activators), glucose oxidation (activating pyruvate dehydrogenase complex), ketone oxidation (increasing ketone plasma levels), hexosamine biosynthesis pathway (O‐GlcNAcylation; administration of glucosamine/glutamine) and deacetylation (activating sirtuins 1 or 3; administration of NAD+‐boosting compounds) all seem to hold promise to reduce acute IRI. In contrast, some metabolic pathways may offer protection through diminished activity. These pathways comprise the malate‐aspartate shuttle (in need of novel specific reversible inhibitors), mitochondrial oxygen consumption, fatty acid oxidation (CD36 inhibitors, malonyl‐CoA decarboxylase inhibitors) and mitochondrial succinate metabolism (malonate). Additionally, protecting the cristae structure of the mitochondria during IR, by maintaining the association of hexokinase II or creatine kinase with mitochondria, or inhibiting destabilization of FOF1‐ATPase dimers, prevents mitochondrial damage and thereby reduces cardiac IRI. Currently, the most promising and druggable metabolic therapy against cardiac IRI seems to be the singular or combined targeting of glycolysis, O‐GlcNAcylation and metabolism of ketones, fatty acids and succinate.Keywords
Funding Information
- Instituto de Salud Carlos III (PI19‐01196)
- European Cooperation in Science and Technology (CA16225)
- National Institutes of Health (R01‐HL‐071158)
This publication has 222 references indexed in Scilit:
- Mitochondrial Cristae Shape Determines Respiratory Chain Supercomplexes Assembly and Respiratory EfficiencyCell, 2013
- Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophyJournal of Molecular and Cellular Cardiology, 2011
- Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)Proceedings of the National Academy of Sciences of the United States of America, 2011
- Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondriaProceedings of the National Academy of Sciences of the United States of America, 2010
- A Ketone Ester Diet Increases Brain Malonyl-CoA and Uncoupling Proteins 4 and 5 while Decreasing Food Intake in the Normal Wistar RatOnline Journal of Public Health Informatics, 2010
- Cardioprotection by metabolic shut-down and gradual wake-upJournal of Molecular and Cellular Cardiology, 2009
- Post-translational modifications of ATP synthase in the heart: biology and functionJournal of Bioenergetics and Biomembranes, 2009
- Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transitionJournal of Molecular and Cellular Cardiology, 2008
- Dimer ribbons of ATP synthase shape the inner mitochondrial membraneThe EMBO Journal, 2008
- Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levelsJournal of Molecular and Cellular Cardiology, 2007